WE HAVE THE TOOLS TO END HIV:
Benefits, Barriers, and Solutions to Expanded Utilization of Pre-exposure Prophylaxis (PrEP) in the US Deep South

June 2016
http://southernaidstrategy.org

Jason Ervin, Duke Law class of 2016
Carolyn McAllaster, Clinical Professor of Law
Director: Southern HIV/AIDS Strategy Initiative
mcallaster@law.duke.edu
INTRODUCTION

The Southeastern United States has the highest HIV diagnosis rate of any US region. In 2014, more than half of national HIV diagnoses reported were located in the Southern United States, which accounted for only 38% of the total US population. The Deep South (the nine-state region comprised of Alabama, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, and Texas) has the highest rate of HIV-related deaths of any US region. From 2008-2013, 21,308 individuals in these states died of HIV as the underlying cause of death, representing 43% of deaths in the US where HIV was the underlying cause. In addition, each of the 9 Deep South states had higher death rates from HIV than the US average from 2008-2013. The Deep South region also leads in racial disparities. In 2013, nearly half (48%) of black gay/MSM diagnosed with HIV in the US lived in the Deep South and the HIV diagnosis rate for black women in the region was 37.5 per 100,000 while the rate for white women was 2.6 per 100,000. The statistics clearly indicate that individuals at risk of HIV infection in the Deep South, particularly African American men and women, are among those most in need of effective HIV prevention tools, and may stand to benefit most from the use of innovative new prevention strategies.

Today, one of the most innovative and effective HIV prevention tools available is PrEP (pre-exposure prophylaxis), which refers to the use of antiretroviral medications (which historically have been used as a method of treatment for HIV-positive individuals after diagnosis) by HIV-negative individuals as a means to prevent HIV infection. Truvada, a drug created and marketed by Gilead Sciences, is the only approved PrEP medication, and, if taken regularly, has been shown to be an incredibly effective method of preventing HIV infection.

---

2 The US Census Bureau defines the South as including Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, Oklahoma, North Carolina, South Carolina, Tennessee, Texas, Virginia, West Virginia.
4 Reif S, Safley D, McAllaster C, A CLOSER LOOK: Deep South has the Highest HIV-related Death Rates in the United States. 2015.
6 See Reif, footnote 5.
7 See Reif, footnote 5.
transmission.\textsuperscript{8} In the open label extension of the often-cited iPrEx study of PrEP efficacy, none of the men who took Truvada at least four times a week contracted HIV.\textsuperscript{9} And in a large study of PrEP users in a Kaiser Permanente Clinical Practice in San Francisco among 657 primarily gay and bi-sexual men, there were no new HIV diagnoses after two and a half years of observation.\textsuperscript{10}

In July of 2012, the US Food and Drug Administration (FDA) approved once-daily Truvada for PrEP, and in May of 2014, the US Centers for Disease Control and Prevention (CDC) recommended that people at 'substantial risk' should consider PrEP to prevent HIV infection.\textsuperscript{11} The World Health Organization (WHO) has also recommended PrEP for people at ‘substantial risk’ of HIV infection.\textsuperscript{12}

Despite its remarkable effectiveness at preventing HIV transmission and the positive response with which it has been met by national and international health organizations, use of PrEP as a prevention strategy has been slow to take hold among some at-risk populations.\textsuperscript{13} The CDC estimates that 1.2 million people in the United States have indications for PrEP use based on their substantial risk of acquiring HIV (24.7% of men who have sex with men, 18.5% of persons who inject drugs and .4% of heterosexually active adults.)\textsuperscript{14}

A number of studies and surveys conducted primarily among vulnerable populations have revealed that barriers to PrEP use continue to exist.

It is worth noting that the majority of US studies related to the efficacy of PrEP and potential barriers to effective PrEP utilization have been conducted among gay men and other men who have sex with men (gay/MSM), since gay/MSM are widely considered most

\begin{itemize}
\item Grant RM et al. Results of the iPrEx open-label extension (iPrEx OLE) in men and transgender women who have sex with men: PrEP uptake, sexual practices, and HIV incidence. 20th International AIDS Conference, Melbourne, abstract TUAC0105LB, 2014.
\item WHO, Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV, Sept. 2015, http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/
\item See Highleyman, footnote 11.
\end{itemize}
at risk of acquiring HIV and of benefiting from PrEP in the US. Despite the fact that certain populations of cisgender women, who account for 20% of all new HIV diagnoses in America, and transgender women are also at high risk of acquiring HIV, US data regarding the efficacy and uptake of PrEP among women is underdeveloped.\(^\text{15}\) Nonetheless, cisgender women who have been surveyed about their knowledge and attitudes towards PrEP had reactions similar to those recorded among gay/MSM, with some expressing initial frustration about their lack of knowledge of the availability of PrEP, and many articulating a willingness to learn more about the drug and an interest in utilizing it as a prevention method if they could gain access to it.\(^\text{16}\) Furthermore, women surveyed about PrEP expressed many of the same reservations about the drug and identified many of the same potential barriers to widespread utilization that are explored in depth in the section below, including concerns about cost, side-effects, stigma, and potential lack of access due to medical mistrust or other factors.\(^\text{17}\)

**BARRIERS TO WIDESPREAD PrEP UTILIZATION IN THE SOUTH**

**Lack of Awareness**

The first and perhaps most prohibitive barrier to widespread PrEP utilization is a simple lack of awareness of the drug’s existence among at-risk populations.

In order for PrEP to be effectively employed as an HIV prevention strategy, potential PrEP users must know about it, understand its risks and benefits, and be willing to take it.\(^\text{18}\) Some studies examining PrEP underutilization have shown that many high-risk individuals who would be excellent candidates for PrEP have not taken it simply because their knowledge about it is limited.\(^\text{19}\)

In one study conducted among young gay/MSM—by far the most high-risk population of any demographic—in 2013, only 27% of study participants reported prior awareness of

---


\(^{16}\) See Auerbach, footnote 15.

\(^{17}\) See Auerbach, footnote 15.


PrEP. A 2014 survey conducted on Manhunt, one of the largest social-networking sites geared towards men who have sex with men, found that only 3.1% of almost 9000 gay/MSM respondents had used PrEP and that “substantial numbers” had not heard of it. A 2015 study conducted among young gay/MSM of color found that only 50% of participants were aware of PrEP prior to their participation in the study. Among participants in this study who did report prior knowledge of PrEP, however, this information was obtained from a variety of sources including the CDC website, Facebook, television reports/news, information obtained from community health agencies, and friends, and from doing their own, independent research.

Across existing studies, awareness of PrEP has been markedly lower among men of color, those who are less highly educated, and those whose primary care providers are not aware of the fact that they have sex with men. Though men with more education or a higher income were much more likely to have heard of PrEP, they were not, according to one report, any more likely to have used it. And in a study conducted among at-risk women (primarily African-American women) in six US cities, less than 10% of those surveyed expressed prior knowledge of PrEP as a preventative measure. Among those high-risk individuals who were not previously aware of PrEP as an HIV prevention strategy, many who participated in studies or surveys about PrEP expressed interest in using it upon learning of its potential for preventing infection.

Although lack of awareness of PrEP among many high-risk populations remains one of the primary barriers to widespread utilization, evidence suggests that in recent years, knowledge

---

23 See Perez-Figueroa, footnote 22.
26 See Auerbach, footnote 15.
of PrEP as a prevention strategy has noticeably increased.\textsuperscript{28} According to data obtained by the CDC through large internet-based surveys of gay, bisexual and other MSM living in the United States (who were recruited via dating apps and websites, social media and gay websites), awareness of PrEP as a prevention strategy increased significantly from 45% in 2012 to 68% in 2015.\textsuperscript{29}

Even as levels of awareness of PrEP are increasing, however, levels of actual PrEP utilization (though also increasing) remain low. In the most recent survey regarding PrEP awareness among American gay/MSM conducted by the CDC in 2015, 68\% of respondents reported knowledge of the existence of PrEP, and 50\% stated that they would be willing to use PrEP (up from 39\% in 2012), but less than 5\% reported having actually used it in the past twelve months (up from 0.5\% in 2012).\textsuperscript{30} Further, rates of PrEP use varied distinctly among respondents based on their location—while 17\% of respondents who live in San Francisco reported using PrEP as prevention (along with 11\% in Seattle, 12\% in New York City, 16\% in Washington DC and around 8\% in Boston, Philadelphia, Chicago and Los Angeles), only 2\% of respondents in rural areas reported doing the same.\textsuperscript{31} This data indicates that even as more individuals become aware of PrEP as a tool for preventing HIV infection, there are other barriers in place, particularly for those who live in smaller cities and more rural parts of the country (like much of the Deep South), that prevent eligible candidates for PrEP from taking advantage of it.

**Lack of Access**

For many high-risk individuals who may qualify as good candidates for PrEP, another barrier to utilization of the drug is lack of access. In order to obtain a prescription for PrEP, a prospective user must have ready access to a clinical care provider who is willing to prescribe it, must themselves be willing to discuss PrEP with their provider and be willing to undergo regular check-ups, as well as HIV tests and other lab tests, and must have access to a pharmacy or other location where the medication can be attained. Many individuals who would like to and would benefit from accessing PrEP may be unwilling or unable to take all the steps necessary to obtain access to it.

In numerous studies and surveys conducted among PrEP-eligible populations, concern about access to PrEP was among the most common barriers cited by participants as a


\textsuperscript{29} Delaney KP et al. Awareness and Use of PrEP Appear to Be Increasing Among Internet Samples of US MSM. Conference on Retroviruses and Opportunistic Infections (CROI 2016), Boston. Abstract 889, 2016.

\textsuperscript{30} See Delaney, footnote 29.

\textsuperscript{31} See Delaney, footnote 29.
reason they might not utilize it. Many at-risk individuals are not linked to medical care relating to sexual health or otherwise, so the concept of having to visit a medical health professional and undergo medical tests regularly may seem daunting or overly complicated. Similarly, some individuals, whether they are linked to care or not, may simply not want to go through all of the necessary requirements to obtain a PrEP prescription for any number of reasons, which may include general mistrust of medical professionals (more common among people of color), perception (whether accurate or not) that doctors do not want to talk about sexual health and therefore will not initiate these conversations, or broader anxiety about/unwillingness to discuss sexual history/practices/needs with a physician.

Furthermore, some prospective PrEP users may have limited access to the drug because they have limited access to medical care in general (for financial or other reasons), or because they live in an area where there are no nearby PrEP/HIV clinics and no medical providers willing to prescribe PrEP.

The fact that some medical providers are unwilling to prescribe PrEP or will only prescribe it in limited circumstances can be a severe barrier for many individuals seeking access to PrEP, so it is worth additional consideration. Though general knowledge about and support for PrEP have increased since the FDA approved Truvada and the CDC released the prescribing guidelines, knowledge of PrEP among providers has increased only slightly, and actual prescribing rates remain relatively low. In one survey of HIV providers in Washington D.C. and Miami (cities with above-average rates of HIV)

---


33 See Brooks, footnote 32.


regarding their knowledge and attitudes about PrEP and willingness to provide it, 53% of surveyed providers agreed that PrEP is effective as an HIV prevention strategy, but only 17% reported ever prescribing it.\textsuperscript{38} In a subsequent national survey of infectious disease specialists, 74% of those surveyed supported PrEP as an HIV prevention strategy, but only 9% reported ever prescribing it.\textsuperscript{39} An earlier online, cross-sectional survey of generalist and HIV specialist physicians in Massachusetts found that 95% of participants said they would be willing to prescribe PrEP in theory, but only 4% had actually prescribed it in the past.\textsuperscript{40}

Providers who have not prescribed PrEP mentioned a laundry list of reasons as to why, including concerns over issues such as drug-related toxicities, the potential development of drug resistance, potential for funds to be diverted from behavioral HIV programs to biomedical programs, concerns over the efficacy data, and fear that PrEP could increase HIV risk behavior.\textsuperscript{41} A 2013 survey of HIV health care providers in the United States found that drug resistance, risk compensation, and adherence were respondents' top 3 concerns, and drug cost was the fourth most common concern.\textsuperscript{42} Other studies have also found that one of the most common perceived barriers to PrEP provision among infectious disease physicians was the belief that the protocol required for effective utilization of the drug is too time-consuming.\textsuperscript{43}

Additional surveys of HIV providers across America have indicated that many are hesitant/unwilling to prescribe PrEP based on previous encounters with HIV-positive patients who did not adhere to life-sustaining treatment and with HIV-negative patients who did not adhere to post-exposure prophylaxis regimens despite an awareness that they were at high-risk for HIV acquisition.\textsuperscript{44} There seems to be a belief among many HIV providers, perhaps shaped by these past experiences, that adherence to PrEP would be low even if they were to prescribe it.\textsuperscript{45} Additionally, lack of specific requests for PrEP by patients are perceived by providers as proof of patient ambivalence and community apathy regarding PrEP, which functions as a sort of self-fulfilling prophecy, confirming in their minds the already present notion that PrEP is ineffective or irrelevant.\textsuperscript{46} Despite these misconceptions, however, most HIV providers believed that PrEP is efficacious if used


\textsuperscript{40} White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. \textit{AIDS Patient Care STDS.} 2012; 26:395–405.

\textsuperscript{41} See White, footnote 40.


\textsuperscript{43} See Karris, footnote 39.

\textsuperscript{44} Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV Providers’ Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study. \textit{AIDS and Behavior.} 2014; 18:1712-1721.

\textsuperscript{45} See Krakower, footnote 44.

\textsuperscript{46} See Krakower, footnote 44.
consistently and that patient requests would motivate them to prescribe it.\textsuperscript{47} The providers also suggested they would be more willing to prescribe PrEP if they knew their colleagues were also doing so.\textsuperscript{48}

Importantly, significant numbers of HIV providers have expressed that they are not in a position to prescribe PrEP since the majority of patients seen by HIV providers are HIV positive and therefore not candidates for PrEP. They also believe that, as a matter of general principle, primary care providers are better situated to make such decisions with their patients.\textsuperscript{49} Surveyed primary care providers suggested the opposite: it is their belief that HIV specialists are better situated to prescribe PrEP.\textsuperscript{50} These differing opinions among categories of providers about who is in the best position to prescribe PrEP to eligible patients create a problematic “purview paradox,” which could limit the accessibility of PrEP for a number of prospective users.\textsuperscript{51}

\textbf{Cost}

The cost of PrEP is another barrier that may inhibit those individuals who could most benefit from PrEP from gaining access to it. A prescription for Truvada for PrEP costs roughly $1,300 per month.\textsuperscript{52} The good news is that Medicaid and private insurance do generally cover the costs of PrEP. For those who are not privately insured, Gilead also offers a prescription assistance program that helps cover the costs of Truvada prescriptions for those eligible.\textsuperscript{53} Gilead also offers a co-pay assistance program to help meet the needs of individuals who are privately insured and who may not be able to afford the co-pays associated with a Truvada prescription.\textsuperscript{54} Furthermore, a small number of community-based organizations in some American cities, like Healthy San Francisco in San Francisco, which seek to make healthcare available to uninsured residents of the city will cover the cost of a PrEP prescription for individuals interested in utilizing PrEP as an HIV prevention strategy but who could not otherwise afford the medication.\textsuperscript{55}

Despite the fact that some financial assistance options are available to prospective PrEP users to help cover the costs of the drug, the fact remains for many individuals, particular uninsured individuals, gaining access to PrEP can still be a costly and, in some cases, prohibitively complicated, process. Successful utilization of PrEP requires a number of actions beyond just taking the daily medication—including frequent doctor visits and

\begin{quote}
\textsuperscript{47} See Krakower, footnote 44.
\textsuperscript{48} See Krakower, footnote 44.
\textsuperscript{49} See Krakower, footnote 44.
\textsuperscript{50} See Krakower, footnote 44.
\textsuperscript{51} See Krakower, footnote 44.
\textsuperscript{52} See Krakower, footnote 44.
\textsuperscript{53} Gilead, \textit{Truvada for PrEP Medication Assistance Program}, \texttt{http://www.gilead.com/responsibility/us-patient-access/truvada\%20for\%20prer\%20medication\%20assistance\%20program}.
\textsuperscript{54} Gilead, \textit{Paying for Truvada}, \texttt{http://www.truvada.com/truvada-patient-assistance}.
\textsuperscript{55} See Healthy San Francisco, \texttt{http://healthysanfrancisco.org/}.
\end{quote}
regular HIV tests and other lab tests—all of which involve additional expenses that may or may not be covered by insurance or other financial assistance programs.

The costs associated with PrEP are often cited by potential PrEP users as one of the most significant barriers to meaningful PrEP utilization. In one study conducted among high-risk gay/MSM, 80% of participants indicated that they would be likely to use PrEP if it was provided free of charge, but 89.3% reported that they would be unlikely to use PrEP if it cost money out of pocket each month. In another study, 416 high-risk gay/MSM were provided with educational counseling regarding rates of HIV transmission and the effectiveness of PrEP as a prophylactic medicine. Each participant was then presented for HIV testing and was offered a prescription for PrEP. Of the 416, only 2 participants (both of whom had private insurance) accepted the prescription and eventually accessed PrEP. When the remaining participants were surveyed regarding why they did not accept the PrEP prescription that was offered to them, 48% reported cost as a major barrier.

Private insurance and Medicaid generally provide coverage for PrEP and Gilead’s Co-pay Assistance Program (CAP) provides assistance for insurance co-pays up to $3,600 per year. Most Southern states, however, have not expanded their Medicaid programs under the Affordable Care Act (ACA). People with incomes below 100% of the federal poverty level remain uninsured because they fall into the so-called coverage gap. They earn too little to qualify for ACA insurance subsidies and they aren’t covered by Medicaid because they live in a state without an expanded Medicaid program. The Kaiser Family Foundation estimates that 90% of people in the coverage gap live in the South.

---


59 See King, footnote 58.

60 See King, footnote 58.

61 See King, footnote 58.


63 [https://www.gileadadvancingaccess.com/hcp/financial-assistance/copay-support](https://www.gileadadvancingaccess.com/hcp/financial-assistance/copay-support)

Because gaining access to PrEP can be expensive, especially for those without insurance, many high-risk individuals, particularly people of color and those of lower socio-economic status do not consider PrEP a viable option for themselves. Some have even reported feeling that PrEP is essentially a “white man’s drug” that is beneficial only for the wealthy, white gay men they feel are less likely to face financial barriers in obtaining PrEP.

**Stigma**

Another factor that is known to negatively impact meaningful PrEP implementation is stigma, which can discourage PrEP use among high-risk individuals on a number of levels.

Many individuals who could benefit from PrEP may choose to avoid it simply because it is an HIV-related medication. Because HIV remains heavily stigmatized today, particularly in the Deep South, even members of the most vulnerable populations may not want to be associated with it in order to avoid being subjected to stigma-related gossip and rejection. Furthermore, the fact that HIV is also in many cases closely associated with other stigmatized subjects like homosexuality, sex work, and drug use may further alienate potential PrEP users and prevent them from seeking access to PrEP for fear that an association with one or more of these categories will be attributed to them. Indeed, studies and surveys of attitudes about PrEP use held by at-risk individuals reveal that many potential PrEP users do not take advantage of PrEP availability for fear that if they are seen doing so, it will make others think (or realize) that they are gay (this concern is especially common among young gay/MSM who are not out to their family or friends), that it will make others think that they are HIV positive, or that it will make their partner/spouse believe that they

65 See Perez-Figueroa, footnote 22.
66 See Perez-Figueroa, footnote 22.
70 See Parker, footnote 69.
are engaging in sex outside of the relationship.\textsuperscript{71} These concerns were found to be particularly common among young African American men.\textsuperscript{72}

Potential PrEP users may be discouraged from accessing the drug because of relentless opposition by the AIDS Healthcare Foundation, led by Michael Weinstein, to the use of PrEP. Though no meaningful evidence has been produced to support the idea that widespread PrEP availability will engender more high-risk behavior, Weinstein argues that PrEP is little more than a “party drug” that will encourage high-risk individuals to engage in unsafe sexual practices further stigmatizing the use of PrEP by potential users.\textsuperscript{73}

A number of PrEP users have confirmed that they have in fact encountered and experienced many of the kinds of stigma that potential PrEP users have identified as deterrents to utilizing PrEP as a prevention strategy from medical providers, friends, sex partners, and others.\textsuperscript{74} Combating this kind of stigma, some experts have suggested, will require a multi-faceted approach, including social-marketing campaigns, education for health care providers, and a broad recognition of PrEP users as individuals proactively using proven prevention strategies.\textsuperscript{75}

\textbf{Adherence}

Another barrier that may inhibit eligible candidates for PrEP is the requirement of adherence. In order for PrEP to be effective prophylaxis, it must be taken regularly—it will not function as an adequate preventative measure if only taken on an as-needed basis. There are gender differences in the level of adherence that may be required. A recent study by University of North Carolina researchers sheds some light on why PrEP may be less effective in women than in gay/MSM.


There are gender differences in the level of [PrEP] adherence that may be required.
Researchers tested how well PrEP is absorbed by the rectum, vagina, and cervix while also looking at the levels of DNA material used by HIV to reproduce that was present. Based on the results and using modeling, researchers calculated the minimal PrEP dose that women and gay/MSM would need to take to achieve protection. They estimated that women would need to take PrEP almost daily while gay/MSM could conceivably achieve protection with two to three doses per week.\textsuperscript{76} Despite this study and though the iPrEx Study found that participants who took PrEP medication at a frequency of approximately four times per week had a comparable level of protection to those who took the medication on a daily basis, it is still recommended that all those seeking to use PrEP as a prevention strategy take the medication once a day in order maintain the highest likelihood of avoiding infection.\textsuperscript{77}

In studies and surveys conducted among high risk populations that asked participants whether they would be likely to adhere to the required PrEP regimen, many said they would not, and offered a number of reasons why. First, the notion of having to take a pill every day was simply deemed burdensome by many and “difficult to sustain over the long term.”\textsuperscript{78} Some participants suggested that they would be unlikely to adhere because they just do not like taking pills, while others commented that, because of irregular daily schedules/sleep patterns or other reasons, they would be likely to forget to take the pills on a consistent basis.\textsuperscript{79} Among those who voiced concern along these lines, as-needed condom usage was generally pointed to as an easier to remember and less burdensome prevention strategy than daily PrEP usage.\textsuperscript{80}

Real world research that looked at PrEP adherence, however, found that adherence levels were generally high. In a study that examined PrEP adherence among 557 gay/MSM in San Francisco, Washington, D.C. and Miami clinics, “80% - 85% had achieved protective drug levels at follow-up visits,” according to Albert Liu, MD, director of HIV Prevention Studies at the San Francisco Department of

\begin{quote}
\textbf{Real world research that looked at PrEP adherence…found that adherence levels were generally high.}
\end{quote}

\textsuperscript{76} Cottrell M et. al, A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis. (2016) doi: 10.1093/infdis/jiw077. See also Science Daily, Women need more of the HIV drug Truvada than men to prevent infection, March 4, 2016, https://www.sciencedaily.com/releases/2016/03/160304092014.htm. “Twice as much of the drug is needed to prevent HIV infection in vaginal and cervical tissue than rectal tissue because fewer components of Truvada make it into those two tissue types. Also, there is more DNA material that the virus uses to reproduce present in vaginal and cervical tissues, thus requiring more of the drug to prevent infection.”

\textsuperscript{77} Amico KR, Psaros C, Safren S, Kofron R, Flynn R, Bolan R, et al. Real time plasma TFV levels to support adherence in a pre-exposure prophylaxis demonstration project. 9th International Conference on HIV Treatment and Prevention Adherence; Abstract 350, 2014 June 8–10; Miami, FL.

\textsuperscript{78} See Perez-Figueroa, footnote 22.

\textsuperscript{79} See Young, footnote 71.

\textsuperscript{80} See Perez-Figueroa, footnote 22.
Health. Lower rates of adherence, however, were found among African-Americans, young people, and those without stable housing. One study concluded that young men who have sex with men in the US “may need access to PrEP in youth-friendly settings with tailored adherence support and potentially augmented visit schedules.” Further research into the factors that contribute to the adherence gap and effective interventions must be considered seriously in any effort to understand and combat barriers to meaningful PrEP usage.

**Attitudes and Misconceptions about Risk / PrEP**

Other barriers that may prevent good candidates for PrEP from utilizing it as a prevention strategy are general attitudes and concerns about the risk of HIV transmission and about the drug itself. In studies that looked at attitudes of young gay/MSM and transgender women, some individuals who were eligible for PrEP did not think it was necessary or would benefit them due to potentially incorrect perceptions about their own susceptibility to risk. Some commented that other methods of prevention, like condoms, are effective, and are also cheaper, more widely available, and less burdensome to use than PrEP, so the need for PrEP is simply not present in their lives. Though Truvada has been shown to be generally well tolerated by users, others expressed concern about possible side effects and the possibility of developing resistance to the medication indicating the need for more widespread education about PrEP.

In a United Kingdom study with gay/MSM and African heterosexual participants, some PrEP candidates indicated that PrEP would not meet their needs as it does not protect against sexually transmitted diseases other than HIV and does not prevent pregnancy.

---

81 See Liu; footnote 75.
82 See Liu, footnote 75.
86 See Young, footnote 71.
87 See Perez-Figueroa, footnote 22.
89 See Young, footnote 71 and Golub, footnote 85.
90 See Young, footnote 71.
Despite evidence to the contrary, others worried that, as a matter of policy, widespread PrEP use would encourage high-risk behaviors among high-risk individuals.91

Further education about the extraordinary protective benefits of PrEP against HIV transmission and wide-reaching recommendations that PrEP be used in combination with other measures such as condoms to prevent other STIs and contraceptives to avoid pregnancy, are needed.

91 See Young, footnote 71.
CONCLUSIONS AND STEPS FORWARD

As discussed in this report, the benefits of PrEP are well established. It is critical that we overcome the multi-faceted barriers to achieving widespread PrEP utilization among vulnerable populations. Many of these barriers may be especially prohibitive in the South, where rates of poverty are higher than the national average, conservative attitudes about sex and HIV may heighten stigma concerns, where few states have expanded their Medicaid programs under the Affordable Care Act, and health outcomes are generally poor.

We know that PrEP, when taken as prescribed, is an effective tool to prevent HIV transmission. Reliance on condom use alone is unlikely to eliminate or even substantially decrease new HIV diagnoses in the US, especially in the South where rates of new diagnoses are highest. Despite the wide spread availability of condoms in recent years, the rates of new HIV diagnoses have remained constant at around 50,000 per year.\(^92\) According to the most recent data released by the CDC, which reports that an estimated 44,784 individuals were diagnosed with HIV in the US in 2014, rates of new HIV diagnoses show no meaningful signs of declining unless new preventative measures like PrEP increase.\(^93\) Because of this, the significance of working to eliminate common barriers to widespread utilization of PrEP cannot be overstated.

Some progress is certainly being made, primarily in larger urban areas. First, the number of PrEP clinics that offer access to Truvada for eligible candidates throughout the South is increasing.\(^94\) For example, in February of 2016, the Health Services Department of Fulton County, Georgia partnered with Gilead Sciences to launch a new PrEP clinic in Atlanta where prescriptions for once-daily Truvada, as well as regular HIV tests and other required lab tests will be offered eligible PrEP candidates free of charge.\(^95\) The new PrEP clinic represents a major step forward in what Fulton County Commission Chair John Eaves called the county’s “aggressive approach” to combatting HIV. “We are going to be a leader like San Francisco, we are going to be a leader like New York City in terms of being

---


aggressive,” Eaves commented, stating at the clinic’s opening “We are here because Fulton County cares. We are here because we have one tool in the toolbox to address the issue.”96 The idea that PrEP is now an important “tool” that can be utilized to help profoundly reduce rates of HIV transmission is beginning to take hold across the South, as a number of other major cities are poised to or have already launched clinics similar to Fulton county’s, a trend which will hopefully prompt a noticeable decline in the number of new HIV diagnoses in the South. 97

In addition to the increase in the number of clinics providing access to PrEP that are now opening across the South, the CDC has also recently introduced funding opportunities that are available to state and local health departments to encourage the provision of PrEP and PrEP-related services to at-risk individuals in larger cities. Among these funding opportunities are CDC-RFA-PS15-1509,98 the purpose of which is to support health departments to collaborate with CBOs, healthcare clinics and providers, behavioral health providers, and social services providers to develop comprehensive models of prevention, care, behavioral health, and social services models for gay/MSM of color living with or at risk for HIV acquisition, and CDC-RFA-PS15-1506, the purpose of which is to support state and local health departments to implement PrEP and Data to Care demonstration projects for populations of gay/MSM and transgender persons at high risk for HIV infection, particularly persons of color.99 In its most recent distribution of funds under these categories, the CDC awarded a number of grants to health departments in the South, including CDC-RFA-PS15-1509 grants to the Virginia State Health Department, the Alabama Department of Public Health, and the Louisiana Department of Health, and CDC-RFA-PS15-1506 grants for PrEP support to large urban areas in Louisiana, Maryland, Virginia, Tennessee, and Texas.

The distribution of federal grants like these, which will be used to support PrEP provision in a number of Southern states and cities, also represents an affirmative step towards eliminating many of the primary barriers that are limiting PrEP utilization in the South. Efforts like these to combat barriers to PrEP need to continue and be expanded to include smaller cities and rural areas and vulnerable populations with heavy HIV burden so that the South will continue to make progress towards achieving widespread utilization of PrEP among high-risk populations. In order to facilitate the continuance of this positive change, a number of recommendations for how to remove barriers and further increase PrEP utilization in the South are offered below.

96 See Henrie, footnote 95.
97 See e.g., information about the Open Arms Clinic in Jackson, MS, http://oahcc.org/.
98 CDC, Funding Announcement PS15-1509: Health Department Demonstration Projects for Comprehensive Prevention, Care, Behavioral Health, and Social Services for Men Who Have Sex with Men (MSM) of Color at Risk for and Living with HIV Infection, http://www.cdc.gov/hiv/funding/announcements/ps15-1509/.
RECOMMENDATIONS:

TO INCREASE PrEP UTILIZATION IN THE SOUTH AND THE US.

Federal Policy Recommendations

- The Centers for Disease Control and Prevention (CDC) should work with the US Department of Health and Human Services, state health departments and community-based organizations to:
  - Develop best practices to reach at-risk persons who could benefit from PrEP;
  - Develop best practices to reach and train primary care medical providers on PrEP;
  - Develop a PrEP surveillance system to measure PrEP utilization.

- The CDC should ensure that CDC funding focused on PrEP:
  - Allows for flexibility to pay for labs and provider time.
  - Is broadened to include smaller cities and rural areas in the South with heavy HIV burden.

- Demonstration Projects are needed that are focused on:
  - PrEP uptake, adherence, and acceptability.
  - The efficacy and utilization of PrEP by and for women, including trans women, sex workers and women of color.

Pharmaceutical Company Policy Recommendations

- Gilead Sciences should:
  - Continue its investment in community-based projects supporting PrEP education for high-risk populations;
  - Invest in a larger PrEP mass media campaign to raise awareness and contribute to the normalization of PrEP use for those at risk.
  - Invest in comprehensive education for primary care providers related to PrEP.
  - Improve its Medication Assistance Program (MAP) for PrEP specifically to allow persons under the age of 26 who are on their parent’s health insurance plan to access the PAP.
Expand the cap on its Co-payment Assistance Program (CAP) contribution from $3600 to match the out-of-pocket maximum cost for Affordable Care Act plans ($6,850 in 2016.)

Provide data on PrEP utilization broken down demographically by gender, race, age, geography and insurance status to identify patterns of and gaps in PrEP uptake.

**State Policy Recommendations**

- State governments, particularly those in the US South, should expand their Medicaid programs under the Affordable Care Act.
- Fund PrEP clinics for vulnerable populations.

**State and Local Health Department Policy Recommendations**

- State and local health departments should:
  - Fund PrEP clinics for vulnerable populations;
  - Raise awareness about PrEP in communities at risk;
  - Work with community-based organizations to educate and engage communities at risk about PrEP.
  - Provide comprehensive PrEP education for primary care providers.